# Who does Dexcom pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/dexcom · Facet: suppliers · Updated: 2026-09-23T09:44:36.635703+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Dexcom discloses no named confirmed suppliers/cost counterparties; 2 relationships are tracked as undisclosed/aggregate. Per the valuechain.wiki graph: 2 cost edges, backed by 3 dated sources, 2 of them primary filings (as of 2026-09-23).

### Verily Health (high)
- metric: Amount $152M · Capitalized upon FDA approval in Q4 2022; carrying value disclosed for FY2025 · Gross intangible asset recognized for the present value of Verily sales-based milestones
- note: Dexcom uses glucose-monitoring technology and intellectual property obtained through its Verily collaboration in products including G7. Its FY2025 Form 10-K reports a $152.4 million Verily intangible asset representing the present value of probable sales-based milestones.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231.htm: "Our prior collaboration with Verily provides us with rights to Verily intellectual property for glucose-monitoring products."
- [confirms] Verily (EN, ir, published 2023-01-11) https://verily.com/stories/one-verily-forward: "They include the development of technology for Dexcom’s G6 and G7 continuous glucose monitors."

### ŌURA (high)
- metric: Amount $75M · Series D announced 2024-11-19 · Dexcom strategic investment in ŌURA's Series D financing
- note: Dexcom invested $75 million in ŌURA's Series D round in November 2024. The companies agreed to connect Dexcom glucose data with Oura Ring sleep, activity, and biometric data and to co-market their products.
- [confirms] Dexcom (EN, ir, published 2024-11-19) https://investors.dexcom.com/news/news-details/2024/Dexcom-and-URA-Announce-Strategic-Partnership/default.aspx: "Dexcom is investing $75 million in ŌURA Series D funding."

### Plexus Corp. (high)
- note: The FDA establishment record identifies a Plexus subsidiary in Mexico as a contract manufacturer for Dexcom ONE and ONE+. Dexcom's manufacturing payments and product-level purchase amounts were not disclosed.
- [confirms] U.S. Food and Drug Administration (EN, filing, published 2026-08-24) https://www.accessdata.fda.gov/scrIpts/cdrh/cfdocs/cfRL/rl.cfm?lid=986717&lpcd=QBJ: "Owner/Operator: PLEXUS CORP. Establishment Operations: Contract Manufacturer."

Reverse side: https://valuechain.wiki/dexcom/customers.md · Ripple: https://valuechain.wiki/dexcom/ripple.md

---
Full node: https://valuechain.wiki/dexcom.md · JSON: https://valuechain.wiki/dexcom.json